why choose us

First received: March 13, 2023

Clinical Trial: Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder

Study Status: Completed

Recruit Status: RECRUITING

Condition: Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder

Study Type: INTERVENTIONAL


Official Title: Phase II Study to Assess the Efficacy of Combined Tafasitamab and Rituximab in Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder

Brief Summary: This phase II trial tests how well tafasitamab and rituximab work for front-line treatment of patients with post-transplant lymphoproliferative disorder.Post-transplant lymphoproliferative disorder (PTLD) is the name for types of lymphoma that sometimes develop in people who have had a transplant.It can affect people who are taking medicines to suppress their immune system.Tafasitamab injection is in a class of medications called monoclonal antibodies.It works by helping the body to slow or stop the growth of…

Read more